SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2096)11/22/2000 11:26:25 AM
From: John Metcalf  Respond to of 52153
 
"The two main points of contact between the biotechs and the political system are the FDA and the drug reimbursement system."

Right; the main political issue has been whether there shall be a Medicare prescription benefit, and opinion was divided on that. Some thought Medicare would spend some of the prescription benefit on biotech drugs, and others thought that the government would drive prices through the floor, erasing any benefit.

If there is still a tiny difference between expectations, it may be that it is hard to imagine Congress passing a prescription benefit for Gore to brag about.



To: Biomaven who wrote (2096)11/22/2000 11:46:15 AM
From: keokalani'nui  Read Replies (1) | Respond to of 52153
 
>>Note that Cantwell is now leading Gorton, so the Senate may well end up split 50:50<<

Up here in Washington, Cantwell's lead for Senate is so slim an automatic recount is now a certainty. Counties must certify by 5pm today. We think we are just as worthy of public attention as our sister state so far away, but CNN seems to prefer warmer climates and choads in winter.

--Wilder


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News